补中益气汤联合化疗治疗非小细胞肺癌作用及药理分析
|
摘要
目的:评价补中益气汤联合化疗治疗非小细胞肺癌的临床疗效。方法:选取符合标准的中晚期非小细胞肺癌患者72例,随机分为治疗组和对照组,每组各36例。对照组采用单纯化疗疗法,治疗组在对照组的基础上给予补中益气汤联合治疗非小细胞肺癌,观察临床疗效。结果:联合补中益气汤的治疗在改善生活质量、缓轻不良反应和改善中医临床症状方面差异有显著性(P<0.05或P<0.01)。结论:补中益气汤联合化疗治疗非小细胞肺癌,具有提高患者的生活质量、减轻化疗的不良反应、改善中医临床症状等方面的效果,并从汤剂的药理学分析了该治疗方案的临床意义。
Objective: To evaluate the clinical effect of Buzhong Yiqi decoction combined with chemotherapy on non-small cell lung cancer.Methods: A total of 72 patients with confirmed diagnosis of non-small cell lung cancer were chose and randomly divided to control group(chemotherapy of TP regimen,n=36) and treatment group(chemotherapy of TP regimen plus Buzhong Yiqi decoction,n=36).The treatment effect,quality of life,drug-induced adverse reactions and traditional Chinese medicine symptom were observed to evaluate the clinical effect.Results: The improvement in quality of life and traditional Chinese medicine clinical symptoms,as well as remission of adverse reactions in treatment group had significant difference(P<0.05 or P<0.01) compared with chemotherapy.Conclusion: It is indicated that Buzhong Yiqi decoction combined with chemotherapy can improve the quality of life of patients,alleviate the adverse reactions of chemotherapy and improve the traditional Chinese medicine clinical symptoms in the treatment of nonsmall cell lung cancer,and the clinical significance of the treatment scheme was explained by the pharmacology pharmacological analysis.
Objective: To evaluate the clinical effect of Buzhong Yiqi decoction combined with chemotherapy on non-small cell lung cancer.Methods: A total of 72 patients with confirmed diagnosis of non-small cell lung cancer were chose and randomly divided to control group(chemotherapy of TP regimen,n=36) and treatment group(chemotherapy of TP regimen plus Buzhong Yiqi decoction,n=36).The treatment effect,quality of life,drug-induced adverse reactions and traditional Chinese medicine symptom were observed to evaluate the clinical effect.Results: The improvement in quality of life and traditional Chinese medicine clinical symptoms,as well as remission of adverse reactions in treatment group had significant difference(P<0.05 or P<0.01) compared with chemotherapy.Conclusion: It is indicated that Buzhong Yiqi decoction combined with chemotherapy can improve the quality of life of patients,alleviate the adverse reactions of chemotherapy and improve the traditional Chinese medicine clinical symptoms in the treatment of nonsmall cell lung cancer,and the clinical significance of the treatment scheme was explained by the pharmacology pharmacological analysis.
引文
[1]Ramalingam SS,Owonikoko TK,Khuri FR.Lung cancer:New biological insights and recent therapeutic advances[J].Ca Cancer J Clin,2011,61(2):91-112.
[2]Scagliotti GV,Parikh P,Pawel JV,et al.Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With AdvancedStage Non-Small-Cell Lung Cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[3]Pignon JP,Tribodet H,Scagliotti GV,et al.Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group[J].J Clin Oncol,2008,26(21):3552-3559.
[4]Douillard JY,Rosell R,Lena MD,et al.Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association[ANITA]):a randomised controlled trial[J].Lancet Oncol,2006,7(9):719-727.
[5]Winton T,Livingston R,Johnson D,et al.Vinorelbine plus cisplatin vs.observation in resected non-small-cell lung cancer[J].N Engl J Med,2005,352(25):2589-2597.
[6]孙一苇,唐文婧.苦参注射液在非小细胞肺癌治疗中的应用效果及其对患者生存质量的影响分析[J].辽宁中医杂志,2014,41(7):1455-1457.
[7]魏亚东,鱼涛,苗文红,等.健脾扶肺汤治疗非小细胞肺癌化疗后疗效观察[J].长春中医药大学学报,2017,33(3):428-30.
[8]赵艳莉,吴召利,李仁廷.扶正祛痰方联合顺铂对LL/2荷瘤小鼠非小细胞肺癌血清IL-2水平的影响[J].陕西中医药大学学报,2017,40(4):101-104.
[9]中华医学会.临床诊疗指南.肿瘤分册[M].北京:人民卫生出版社,2009.
[10]田德禄,蔡淦.中医内科学[M].2版.上海:上海科学技术出版社,2013.
[11]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[A].中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院.第三届中国肿瘤内科大会教育集暨论文集[C].中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院:中国抗癌协会,2009:3.
[12]中国华人民共和国卫生部.中国常见恶性肿瘤诊治规范[M].北京:北京医科大学、中国协和医科大学联合出版社,1991.
[13]胡夕春.肿瘤内科方案的药物不良反应及对策[M].北京:人民卫生出版社,2009.
[14]张培彤,于明薇,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7):702-705.
[15]李富秀.中西医结合治疗老年晚期非小细胞肺癌疗效及安全性探讨[J].中国地方病防治杂志,2017,32(5):501-502.
[16]戴新,徐道静.中药+化疗共同治疗晚期非小细胞肺癌的疗效与对患者生存期的相关影响[J].中国继续医学教育,2017,9(18):186-188.
[17]李杰,林洪生,孙桂芝.中医药治疗肿瘤研究现状的反思及展望[J].中医药学刊,2005(6):1077-1079.
[18]范存伟,李珍.补中益气汤主要药物的新药理作用[J].医药产业资讯,2005(15):117-128.
[19]Chen R,Shao H,Lin S,et al.Treatment with Astragalus membranaceus Produces Antioxidative Effects and Attenuates Intestinal Mucosa Injury Induced by Intestinal IschemiaReperfusion in Rats[J].Am J Chin Med,2011,39(5):879-887.
[20]李晓冬,李俊,李荣,等.橙皮苷对刀豆蛋白A致小鼠免疫性肝损伤的保护作用[J].安徽医科大学学报,2010,45(3):350-353.
[2]Scagliotti GV,Parikh P,Pawel JV,et al.Phase III Study Comparing Cisplatin Plus Gemcitabine With Cisplatin Plus Pemetrexed in Chemotherapy-Naive Patients With AdvancedStage Non-Small-Cell Lung Cancer[J].J Clin Oncol,2008,26(21):3543-3551.
[3]Pignon JP,Tribodet H,Scagliotti GV,et al.Lung adjuvant cisplatin evaluation:a pooled analysis by the LACE Collaborative Group[J].J Clin Oncol,2008,26(21):3552-3559.
[4]Douillard JY,Rosell R,Lena MD,et al.Adjuvant vinorelbine plus cisplatin versus observation in patients with completely resected stage IB-IIIA non-small-cell lung cancer(Adjuvant Navelbine International Trialist Association[ANITA]):a randomised controlled trial[J].Lancet Oncol,2006,7(9):719-727.
[5]Winton T,Livingston R,Johnson D,et al.Vinorelbine plus cisplatin vs.observation in resected non-small-cell lung cancer[J].N Engl J Med,2005,352(25):2589-2597.
[6]孙一苇,唐文婧.苦参注射液在非小细胞肺癌治疗中的应用效果及其对患者生存质量的影响分析[J].辽宁中医杂志,2014,41(7):1455-1457.
[7]魏亚东,鱼涛,苗文红,等.健脾扶肺汤治疗非小细胞肺癌化疗后疗效观察[J].长春中医药大学学报,2017,33(3):428-30.
[8]赵艳莉,吴召利,李仁廷.扶正祛痰方联合顺铂对LL/2荷瘤小鼠非小细胞肺癌血清IL-2水平的影响[J].陕西中医药大学学报,2017,40(4):101-104.
[9]中华医学会.临床诊疗指南.肿瘤分册[M].北京:人民卫生出版社,2009.
[10]田德禄,蔡淦.中医内科学[M].2版.上海:上海科学技术出版社,2013.
[11]冯奉仪.实体瘤新的疗效评价标准(解读1.1版RECIST标准)[A].中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院.第三届中国肿瘤内科大会教育集暨论文集[C].中国癌症基金会、中国抗癌协会肿瘤临床化疗专业委员会、中华医学会肿瘤学分会、全国肿瘤防治研究办公室、中国医学科学院肿瘤医院:中国抗癌协会,2009:3.
[12]中国华人民共和国卫生部.中国常见恶性肿瘤诊治规范[M].北京:北京医科大学、中国协和医科大学联合出版社,1991.
[13]胡夕春.肿瘤内科方案的药物不良反应及对策[M].北京:人民卫生出版社,2009.
[14]张培彤,于明薇,杨宗艳,等.中晚期非小细胞肺癌中西医疗效评价方法比较研究[J].中国中西医结合杂志,2010,30(7):702-705.
[15]李富秀.中西医结合治疗老年晚期非小细胞肺癌疗效及安全性探讨[J].中国地方病防治杂志,2017,32(5):501-502.
[16]戴新,徐道静.中药+化疗共同治疗晚期非小细胞肺癌的疗效与对患者生存期的相关影响[J].中国继续医学教育,2017,9(18):186-188.
[17]李杰,林洪生,孙桂芝.中医药治疗肿瘤研究现状的反思及展望[J].中医药学刊,2005(6):1077-1079.
[18]范存伟,李珍.补中益气汤主要药物的新药理作用[J].医药产业资讯,2005(15):117-128.
[19]Chen R,Shao H,Lin S,et al.Treatment with Astragalus membranaceus Produces Antioxidative Effects and Attenuates Intestinal Mucosa Injury Induced by Intestinal IschemiaReperfusion in Rats[J].Am J Chin Med,2011,39(5):879-887.
[20]李晓冬,李俊,李荣,等.橙皮苷对刀豆蛋白A致小鼠免疫性肝损伤的保护作用[J].安徽医科大学学报,2010,45(3):350-353.